FINANCINGS
Affigen LLC closed a $17 million series A financing round.
Biostage Inc. closed its public offering of 20 million shares of common stock and warrants to purchase 20 million shares for total gross proceeds of $8 million.
Braeburn Pharmaceuticals Inc. withdrew its planned IPO, blaming "terms currently obtainable in the public marketplace" as "not sufficiently attractive."
Fusion Pharmaceuticals Inc. has raised $25 million from a series A round.
Global Blood Therapeutics Inc. priced an upsized public offering of about 5.1 million shares of common stock at $24.50 per share for gross proceeds of about $125 million.
Oncternal Therapeutics Inc. said it closed an $18.4 million series B financing.
PMV Pharmaceuticals Inc. has landed a $74 million series B financing.
DEALS
Abzena plc signed a manufacturing agreement with University College London under which Abzena will manufacture magacizumab at its biomanufacturing facility in San Diego.
Astrazeneca plc entered an agreement with Tersera Therapeutics LLC for the commercial rights to Zoladex (goserelin acetate implant) in the U.S. and Canada. Zoladex is an injectable luteinizing hormone-releasing hormone agonist used to treat prostate cancer, breast cancer and certain benign gynecological disorders.
Auris Medical Holding AG has extended its collaboration with King's College London, which is focused on the discovery of small-molecule compounds for a second-generation tinnitus treatment.
Benitec Biopharma Ltd. has signed a deal with Nantworks Inc. that expands its pipeline into oncology.
Capricor Therapeutics Inc. is terminating its license agreement with the Mayo Clinic relating to natriuretic peptide receptor agonists, including cenderitide.
Exelixis Inc. and Takeda Pharmaceutical Co. Ltd. reached an exclusive licensing agreement for the commercialization and further clinical development in Japan of oncology drug cabozantinib.
Santen Inc., the U.S. subsidiary of Santen Pharmaceutical Co. Ltd., and Twoxar Inc. have entered a strategic research collaboration focused on the identification of new drug candidates for glaucoma.
. . . AND MORE
Abbvie Inc. said its board has authorized a $5 billion increase to the company's existing stock repurchase program.
Aphios Corp. spun off Aphios Pharma to develop FDA-approved, cannabis-based drugs for treating highly unmet central nervous system disorders.
Arch Biopartners Inc. said its common shares began trading under the new symbol ARCH on the TSX Venture Exchange.
Argos Therapeutics Inc. is stopping the pivotal phase III ADAPT trial of lead candidate rocapuldencel-T (roca, formerly AGS-003) for futility on the advice of the independent data monitoring committee.
Cell Medica Ltd. said the FDA granted fast track designation to lead oncology drug CMD-003 for patients with relapsed/refractory lymphoma and post-transplant lymphoproliferative disease associated with the oncogenic Epstein-Barr virus.
Celltrion Healthcare Inc. received European Commission approval of Truxima, a biosimilar to Rituxan (rituximab, Roche Holding AG/Biogen Inc.).
Cyclacel Pharmaceuticals Inc. said top-line results from the phase III SEAMLESS study testing nucleoside analogue sapacitabine in elderly patients with newly diagnosed acute myeloid leukemia did not meet the primary endpoint of demonstrating statistically significant improvement in overall survival.
Just three years in, the U.S. BRAIN project has led to the development of a number of new high-speed, non-invasive methods for imaging neuronal activity that are starting to transform basic research in neuroscience and pointing toward novel approaches to treating brain diseases.
Pfizer Inc. said a BLA for inotuzumab ozogamicin was accepted for filing and granted priority review by the FDA for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.
The Pharmaceutical Research and Manufacturers of America Foundation said it has launched its new value assessment initiative, a three-part award program aimed at advancing the ongoing shift toward a value-driven health care system through better evidence and value frameworks.
Sarepta Therapeutics Inc. gained $125 million by selling to Gilead Sciences Inc. an FDA priority review voucher won with its approval of Exondys 51 (eteplirsen).